{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:15:02Z","timestamp":1785798902721,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272045"],"award-info":[{"award-number":["82272045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801740"],"award-info":[{"award-number":["81801740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ20096"],"award-info":[{"award-number":["2022JJ20096"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Hunan Provincial Health Commision","award":["C202309048470"],"award-info":[{"award-number":["C202309048470"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00259-025-07089-2","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:40:19Z","timestamp":1737794419000},"page":"2051-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Which patients with negative PSMA-PET imaging can safely avoid biopsy for prostate cancer? a novel step towards PSMA-based biopsy-free strategy"],"prefix":"10.1007","volume":"52","author":[{"given":"Yujia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8943","authenticated-orcid":false,"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"7089_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/s0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-ShaterBosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(16)32401-1.","journal-title":"Lancet"},{"key":"7089_CR2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","volume":"75","author":"DC Johnson","year":"2019","unstructured":"Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2019;75:712\u201320. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.031.","journal-title":"Eur Urol"},{"key":"7089_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol. 2020;78:402\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.048.","journal-title":"Eur Urol"},{"key":"7089_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.juro.2018.08.046","volume":"201","author":"M Oishi","year":"2019","unstructured":"Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, et al. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer? J Urol. 2019;201:268\u201376. https:\/\/doi.org\/10.1016\/j.juro.2018.08.046.","journal-title":"J Urol"},{"key":"7089_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.eururo.2018.03.007","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, et al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What\u2019s Next? Eur Urol. 2018;74:48\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2018.03.007.","journal-title":"Eur Urol"},{"key":"7089_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bju.13657","volume":"119","author":"N Branger","year":"2017","unstructured":"Branger N, Maubon T, Traumann M, Thomassin-Piana J, Brandone N, Taix S, et al. Is negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience. BJU Int. 2017;119:449\u201355. https:\/\/doi.org\/10.1111\/bju.13657.","journal-title":"BJU Int"},{"key":"7089_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.04.005","author":"WI Luining","year":"2024","unstructured":"Luining WI, Boev\u00e9 LMS, Hagens MJ, Meijer D, de Weijer T, Ettema RH, et al. A Comparison of Globally Applied Prognostic Risk Groups and the Prevalence of Metastatic Disease on Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.04.005.","journal-title":"Eur Urol Oncol"},{"key":"7089_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021;80:682\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002.","journal-title":"Eur Urol"},{"key":"7089_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63:1644\u201350. https:\/\/doi.org\/10.2967\/jnumed.121.263448.","journal-title":"J Nucl Med"},{"key":"7089_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/rlu.0000000000004951","volume":"49","author":"S Guo","year":"2024","unstructured":"Guo S, Kang F, Ma S, Jiao J, Ren J, Wang J, et al. The PRIMARY Score: Diagnostic Performance and Added Value Compared With MRI in Detecting Clinically Significant Prostate Cancer. Clin Nucl Med. 2024;49:37\u201344. https:\/\/doi.org\/10.1097\/rlu.0000000000004951.","journal-title":"Clin Nucl Med"},{"key":"7089_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The Impact of (68)Ga-PSMA PET\/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med. 2018;59:82\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.197160.","journal-title":"J Nucl Med"},{"key":"7089_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, et al. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024;65:94\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266164.","journal-title":"J Nucl Med"},{"key":"7089_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"7089_CR14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00259-023-06142-2","volume":"50","author":"X Gao","year":"2023","unstructured":"Gao X, Tang Y, Chen M, Li J, Yin H, Gan Y, et al. A prospective comparative study of [(68)Ga]Ga-RM26 and [(68)Ga]Ga-PSMA-617 PET\/CT imaging in suspicious prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:2177\u201387. https:\/\/doi.org\/10.1007\/s00259-023-06142-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7089_CR15","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00259-021-05636-1","volume":"49","author":"DX Qiu","year":"2022","unstructured":"Qiu DX, Li J, Zhang JW, Chen MF, Gao XM, Tang YX, et al. Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49:2821\u201332. https:\/\/doi.org\/10.1007\/s00259-021-05636-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7089_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-024-01116-3","volume":"14","author":"L Xiao","year":"2024","unstructured":"Xiao L, Fang Z, Tang Y, Sun Y, Zhu Z, Li J, et al. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. EJNMMI Res. 2024;14:55. https:\/\/doi.org\/10.1186\/s13550-024-01116-3.","journal-title":"EJNMMI Res"},{"key":"7089_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.urolonc.2012.03.002","volume":"31","author":"BE Weiss","year":"2013","unstructured":"Weiss BE, Wein AJ, Malkowicz SB, Guzzo TJ. Comparison of prostate volume measured by transrectal ultrasound and magnetic resonance imaging: is transrectal ultrasound suitable to determine which patients should undergo active surveillance? Urol Oncol. 2013;31:1436\u201340. https:\/\/doi.org\/10.1016\/j.urolonc.2012.03.002.","journal-title":"Urol Oncol"},{"key":"7089_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76:340\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033.","journal-title":"Eur Urol."},{"key":"7089_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"7089_CR20","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/pas.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u201399. https:\/\/doi.org\/10.1097\/pas.0000000000001497.","journal-title":"Am J Surg Pathol."},{"key":"7089_CR21","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901\u201313. https:\/\/doi.org\/10.1001\/jama.2018.3710.","journal-title":"JAMA"},{"key":"7089_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1741-7015-12-26","volume":"12","author":"AJ Vickers","year":"2014","unstructured":"Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, et al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med. 2014;12:26. https:\/\/doi.org\/10.1186\/1741-7015-12-26.","journal-title":"BMC Med"},{"key":"7089_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ju.0000000000004010","volume":"212","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, et al. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography\/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024;212:299\u2013309. https:\/\/doi.org\/10.1097\/ju.0000000000004010.","journal-title":"J Urol"},{"key":"7089_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00782-z","author":"S Guo","year":"2023","unstructured":"Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, et al. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00782-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7089_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00259-018-4255-1","volume":"46","author":"J Zhang","year":"2019","unstructured":"Zhang J, Shao S, Wu P, Liu D, Yang B, Han D, et al. Diagnostic performance of (68)Ga-PSMA PET\/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging. 2019;46:908\u201320. https:\/\/doi.org\/10.1007\/s00259-018-4255-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7089_CR26","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231879","volume":"311","author":"BM Priv\u00e9","year":"2024","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Janssen MJR, van der Leest MMG, de Rooij M, van Ipenburg JA, et al. Multiparametric MRI and (18)F-PSMA-1007 PET\/CT for the Detection of Clinically Significant Prostate Cancer. Radiology. 2024;311: e231879. https:\/\/doi.org\/10.1148\/radiol.231879.","journal-title":"Radiology"},{"key":"7089_CR27","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.7150\/thno.58140","volume":"11","author":"J Jiao","year":"2021","unstructured":"Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET\/CT: a real-world study. Theranostics. 2021;11:8396\u2013411. https:\/\/doi.org\/10.7150\/thno.58140.","journal-title":"Theranostics"},{"key":"7089_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7089_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-Head Comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. J Nucl Med. 2022;63:847\u201354. https:\/\/doi.org\/10.2967\/jnumed.121.262398.","journal-title":"J Nucl Med"},{"key":"7089_CR30","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578\u201382. https:\/\/doi.org\/10.1073\/pnas.1106383108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7089_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z","author":"MK Bakht","year":"2024","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2024. https:\/\/doi.org\/10.1038\/s41585-024-00900-z.","journal-title":"Nat Rev Urol"},{"key":"7089_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/ju.0000000000004025","volume":"212","author":"S Niu","year":"2024","unstructured":"Niu S, Ding X, Liu B, Ao L, Wang H, Chen W, et al. Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography\/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective. Single-Arm Trial J Urol. 2024;212:280\u20139. https:\/\/doi.org\/10.1097\/ju.0000000000004025.","journal-title":"Single-Arm Trial J Urol"},{"key":"7089_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eururo.2021.11.019","volume":"82","author":"VH Meissner","year":"2022","unstructured":"Meissner VH, Rauscher I, Schwamborn K, Neumann J, Miller G, Weber W, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. 2022;82:156\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2021.11.019.","journal-title":"Eur Urol"},{"key":"7089_CR34","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","volume":"51","author":"K Akcay","year":"2024","unstructured":"Akcay K, Kibar A, Sahin OE, Demirbilek M, Beydagi G, Asa S, et al. Prediction of clinically significant prostate cancer by [(68) Ga]Ga-PSMA-11 PET\/CT: a potential tool for selecting patients for active surveillance. Eur J Nucl Med Mol Imaging. 2024;51:1467\u201375. https:\/\/doi.org\/10.1007\/s00259-023-06556-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7089_CR35","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.2967\/jnumed.122.265001","volume":"64","author":"J Zhang","year":"2023","unstructured":"Zhang J, Kang F, Gao J, Jiao J, Quan Z, Ma S, et al. A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study. J Nucl Med. 2023;64:1750\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.265001.","journal-title":"J Nucl Med"},{"key":"7089_CR36","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2967\/jnumed.124.268443","volume":"65","author":"I Sonni","year":"2024","unstructured":"Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, et al. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET\/CT and Multiparametric MRI. J Nucl Med. 2024;65:1923\u201331. https:\/\/doi.org\/10.2967\/jnumed.124.268443.","journal-title":"J Nucl Med"},{"key":"7089_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06949-7","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Yang J, Xiao L, Zhou M, Cai Y, et al. Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS \u2264 3 MRI. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06949-7.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07089-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:27:00Z","timestamp":1745317620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07089-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7089"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07089-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AR and KS are editors of the journal European Journal of Nuclear Medicine and Molecular Imaging. RS has received research\/travel support from the Boehringer Ingelheim Fund and the Else Kr\u00f6ner-Fresenius-Stiftung. The other authors have no relevant financial or non-financial conflicts of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Xiangya Hospital, Central South University (201909253) and ethics review board (NCT05073653, Registration Date: 2021\u201310-11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and photograph.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}